Format

Send to

Choose Destination
Kidney Int. 2017 Nov;92(5):1261-1271. doi: 10.1016/j.kint.2017.04.028. Epub 2017 Jul 24.

Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland.

Author information

1
National Renal Complement Therapeutics Centre, Newcastle University, Newcastle upon Tyne, UK.
2
Great North Children's Hospital, Sir James Spence Institute, Royal Victoria Infirmary, Newcastle, UK.
3
Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
4
University Hospital Southampton NHS Foundation Trust, Southampton, UK.
5
Leeds Teaching Hospitals NHS Trust, Leeds, UK.
6
The Department for Paediatric Nephrology & Transplantation, The Children's University Hospital, Dublin, Ireland.
7
Department of Paediatric Nephrology, Royal Manchester Children's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
8
University Hospital of Wales, Cardiff, Wales.
9
Guy's and St Thomas' NHS Foundation Trust, London, UK.
10
Birmingham Children's Hospital NHS Foundation Trust, Birmingham, UK.
11
UCL Centre for Nephrology, Royal Free London NHS Foundation Trust, Rowland Hill Street, London, UK.
12
Southend University Hospital, Prittlewell Chase, Westcliff-on-Sea, UK.
13
Department of Paediatric Nephrology, Bristol Royal Hospital for Children, Bristol, UK.
14
Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
15
National Renal Complement Therapeutics Centre, Newcastle University, Newcastle upon Tyne, UK. Electronic address: david.kavanagh@ncl.ac.uk.

Abstract

Factor H autoantibodies can impair complement regulation, resulting in atypical hemolytic uremic syndrome, predominantly in childhood. There are no trials investigating treatment, and clinical practice is only informed by retrospective cohort analysis. Here we examined 175 children presenting with atypical hemolytic uremic syndrome in the United Kingdom and Ireland for factor H autoantibodies that included 17 children with titers above the international standard. Of the 17, seven had a concomitant rare genetic variant in a gene encoding a complement pathway component or regulator. Two children received supportive treatment; both developed established renal failure. Plasma exchange was associated with a poor rate of renal recovery in seven of 11 treated. Six patients treated with eculizumab recovered renal function. Contrary to global practice, immunosuppressive therapy to prevent relapse in plasma exchange-treated patients was not adopted due to concerns over treatment-associated complications. Without immunosuppression, the relapse rate was high (five of seven). However, reintroduction of treatment resulted in recovery of renal function. All patients treated with eculizumab achieved sustained remission. Five patients received renal transplants without specific factor H autoantibody-targeted treatment with recurrence in one who also had a functionally significant CFI mutation. Thus, our current practice is to initiate eculizumab therapy for treatment of factor H autoantibody-mediated atypical hemolytic uremic syndrome rather than plasma exchange with or without immunosuppression. Based on this retrospective analysis we see no suggestion of inferior treatment, albeit the strength of our conclusions is limited by the small sample size.

KEYWORDS:

acute kidney injury; atypical hemolytic uremic syndrome; complement; factor H autoantibodies; thrombotic microangiopathy

PMID:
28750931
PMCID:
PMC5652378
DOI:
10.1016/j.kint.2017.04.028
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center